MedTrace Logo

Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer

NCT00215709 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2007-11-19

No results posted yet for this study

Summary

This pilot study is designed to determine the feasibility and safety of administering docetaxel at various dosing levels on a bi-weekly schedule in older men with hormone refractory prostate cancer.

Conditions

Interventions

DRUG

docetaxel

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Geriatric Oncology Consortium

    lead OTHER

Principal Investigators

  • William Ershler, MD · Geriatric Oncology Consortium

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00215709 on ClinicalTrials.gov